Details of the Drug

General Information of Drug (ID: DM9KJLZ)

Drug Name

Foscavir

Synonyms

Foscarmet; Foscarnet; Phosphonoformate; Triapten; Virudin; Carboxyphosphonic acid; Dihydroxyphosphanecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide trisodium salt; Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate; FOSCARNET SODIUM; Forscarnet sodium; Foscarnet sodico; Foscarnet sodico [Spanish]; Foscarnet sodique; Foscarnet sodique [French]; Foscarnet sodium hexahydrate; Foscarnet sodium hydrate; Foscarneto sodico; Foscarnetum natricum; Foscarnetum natricum [Latin]; Phgosphonocarboxylic acid; Phosphonoformic acid; Phosphonomethanoic acid; Trisodium carboxyphosphate; Trisodium dioxidophosphanecarboxylate oxide; Trisodium dioxidophosphinecarboxylate oxide; Trisodium phosphonatoformate; Trisodium phosphonatoformate hexahydrate; Trisodium phosphonoformate; Trisodium phosphonoformate hexahydrate; Trisodium phosphonoformte hexahydrate; A 29622; EHB 776; A-29622; DRG-0017; Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody; EHB-776; Foscarnet sodique [INN-French]; Foscarnet sodium hydrate (JAN); Foscarneto sodico [INN-Spanish]; Foscarnetum natricum [INN-Latin]; Foscavir (TN); HS-0008; MSL & PFA; Phosphonoformic acid, trisodium salt; Trisodium carboxyphosphate (anhydrous); Trisodium phosphonoformate (anhydrous); Foscarnet & IFN-ALPHA; Foscarnet sodium (USAN/INN); Foscarnet sodium [USAN:INN:BAN]; Phosphonoformic acid & IFN-ALPHA; Phosphonoformic acid, trisodium salt, hexahydrate; PFA & rIFN.alpha.A; Phosphinecarboxylic acid, dihydroxy-, oxide; Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon; Sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6); Formic acid, phosphono-, trisodium salt, hexahydrate; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate

Indication

Disease Entry	ICD 11	Status	REF
Cytomegalovirus retinitis	9B72.00	Approved	[1]

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

191.95

Topological Polar Surface Area

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 3.3 - 6.8 hours [2]
Metabolism: The drug is not metabolised [3]

Chemical Identifiers

Formula: CNa3O5P
IUPAC Name: trisodium;phosphonatoformate
Canonical SMILES: C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]
InChI: InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3
InChIKey: DFHAXXVZCFXGOQ-UHFFFAOYSA-K

Cross-matching ID

PubChem CID: 44561
ChEBI ID: CHEBI:141644
CAS Number: 63585-09-1
TTD ID: D0OT0O
ACDINA ID: D01104

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Herpes simplex virus DNA polymerase UL30 (HSV UL30)	TTIU7X1	DPOL_HHV11	Inhibitor	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Hydrochloric acid	E00015	313	Acidulant
Water	E00035	962	Solvent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Foscarnet Sodium 600mg/250ml injectable	600mg/250ml	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020068.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
5	Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81.
8	Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15.
9	Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66.
10	Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8.
11	Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999 Feb;57(2):187-206.